Abstract
Consequential health decisions in the United States are often made behind closed doors without input from patients and other critical stakeholders. The Institute for Clinical and Economic Review (ICER) brings drug pricing and coverage decisions into the open by conducting independent assessments of effectiveness and value that undergo a public process. While many stakeholders are invited to participate, ICER's dedicated patient engagement program demonstrates a strong commitment to those most impacted by the final report conclusions and recommendations. ICER believes that patients should have a voice in decisions that directly affect their ability to afford and access treatment.